A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Study Title
An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)
Teva Identifier
TV50717-CNS-30081 | 2019-001807-19
ClinicalTrials.gov Identifier
NCT04200352
Study Status
Terminated
Trial Condition(s)
Cerebral Palsy, Dyskinetic
Interventions
Drug: TEV-50717
EudraCT Number
2019-001807-19
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
brain-icon

Key Participation Requirements

Gender
Female, Male
Age group
Child, Adult
Age Range
6 Years to 18 Years
Trial Duration
February 04, 2020 - February 14, 2023
Phase
Phase 3

Additional info

Study Type

Interventional

Location - Where to Participate

You may contact 1-888-483-8279 or email USMedInfo@tevapharm.com to obtain more information about study locations.